22.11.2012 • News • Talison • Mergers & Acquisitions (M&A) • chemical industry

Talison Lithium to Talk with China's Tianqi on Takeover

Talison Lithium said on Wednesday that it will hold talks with Chengdu Tianqi Industry Group to determine if the Chinese company's takeover offer represents a "superior proposal," as defined under an existing friendly deal with Rockwood Holdings.

Tianqi's C$7.15-a-share offer, which values the Perth-based, Toronto-listed lithium producer at C$806 million ($807.66 million), is 65 Canadian cents a share higher than the bid from Rockwood, a U.S.-based chemical producer.

A "superior proposal" takes into account the monetary value of the offer, the likelihood of conditions being attached to a takeover, and the timing required to complete a deal.

Talison produces hard rock lithium at its Greenbushes lithium project in Western Australia, primarily for export to China. The company also owns the Salares 7 lithium brine project in Northern Chile.

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Top-Feature

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.